Allergan Debt to Equity Ratio 2006-2018 | AGN

Current and historical debt to equity ratio values for Allergan (AGN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Allergan debt/equity for the three months ending September 30, 2018 was 0.32.
Allergan Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $22.23B $70.52B 0.32
2018-06-30 $24.00B $71.26B 0.34
2018-03-31 $25.94B $72.35B 0.36
2017-12-31 $25.84B $68.91B 0.38
2017-09-30 $26.54B $66.24B 0.40
2017-06-30 $26.44B $70.30B 0.38
2017-03-31 $26.22B $70.27B 0.37
2016-12-31 $29.97B $71.27B 0.42
2016-09-30 $31.18B $84.80B 0.37
2016-06-30 $37.08B $71.71B 0.52
2016-03-31 $38.55B $72.52B 0.53
2015-12-31 $40.13B $71.66B 0.56
2015-09-30 $40.65B $72.55B 0.56
2015-06-30 $41.32B $72.08B 0.57
2015-03-31 $42.70B $66.48B 0.64
2014-12-31 $14.84B $28.34B 0.52
2014-09-30 $15.09B $29.15B 0.52
2014-06-30 $10.74B $9.69B 1.11
2014-03-31 $8.45B $9.63B 0.88
2013-12-31 $8.52B $9.54B 0.89
2013-09-30 $5.68B $3.75B 1.52
2013-06-30 $6.17B $3.54B 1.74
2013-03-31 $6.24B $3.62B 1.72
2012-12-31 $6.26B $3.86B 1.62
2012-09-30 $1.02B $3.69B 0.28
2012-06-30 $1.10B $3.56B 0.31
2012-03-31 $1.16B $3.66B 0.32
2011-12-31 $0.85B $3.56B 0.24
2011-09-30 $1.15B $3.49B 0.33
2011-06-30 $1.03B $3.47B 0.30
2011-03-31 $1.02B $3.37B 0.30
2010-12-31 $1.02B $3.28B 0.31
2010-09-30 $1.16B $3.22B 0.36
2010-06-30 $1.16B $3.14B 0.37
2010-03-31 $1.16B $3.09B 0.37
2009-12-31 $1.15B $3.02B 0.38
2009-09-30 $1.00B $2.31B 0.43
2009-06-30 $0.15B $2.23B 0.07
2009-03-31 $0.25B $2.16B 0.12
2008-12-31 $0.83B $2.11B 0.39
2008-09-30 $0.83B $2.05B 0.40
2008-06-30 $0.83B $1.97B 0.42
2008-03-31 $0.82B $1.90B 0.43
2007-12-31 $0.90B $1.85B 0.49
2007-09-30 $0.97B $1.81B 0.54
2007-06-30 $0.97B $1.77B 0.55
2007-03-31 $1.07B $1.71B 0.63
2006-12-31 $1.12B $1.68B 0.67
2006-09-30 $0.57B $2.17B 0.27
2006-06-30 $0.57B $2.13B 0.27
2006-03-31 $0.57B $2.14B 0.27
2005-12-31 $0.59B $2.10B 0.28
2005-09-30 $0.59B $2.09B 0.28
2005-06-30 $0.59B $2.15B 0.27
2005-03-31 $0.59B $2.22B 0.27
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $55.828B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $23.846B 7.31
Mylan (MYL) United Kingdom $19.053B 7.84
Bausch Health Cos (BHC) Canada $9.511B 6.89
Dr Reddy's Laboratories (RDY) India $5.520B 22.05
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.574B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.364B 22.41
Amphastar Pharmaceuticals (AMPH) United States $0.999B 107.95
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.755B 0.00
CymaBay Therapeutics (CBAY) United States $0.687B 0.00
Assembly Biosciences (ASMB) United States $0.596B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.457B 0.00
Corium (CORI) United States $0.457B 0.00
Voyager Therapeutics (VYGR) United States $0.401B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.325B 0.00
Teligent (TLGT) United States $0.174B 0.00
Sol-Gel Technologies (SLGL) Israel $0.133B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.105B 0.00
Aevi Genomic Medicine (GNMX) United States $0.084B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Acasti Pharma (ACST) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.047B 0.00
Agile Therapeutics (AGRX) United States $0.034B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00